DGAP-News

Sangui BioTech International Inc.: British National Health Service NHS granted wound spray Granulox reimbursement

DGAP-News: Sangui BioTech International Inc. / Key word(s): Market launch
Sangui BioTech International Inc.: British National Health Service NHS
granted wound spray Granulox reimbursement

04.10.2016 / 10:09
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Sangui BioTech:

- British National Health Service NHS granted wound spray Granulox
reimbursement

- British National Health Service NHS confirmed effectiveness and
efficiency of Granulox

- Cost savings of several thousand British pounds per patient


Witten, Germany, September 30, 2016 - The SastoMed GmbH has announced that
the British National Health Service (NHS) has taken the wound spray
Granulox licensed by Sangui to SastoMed GmbH on the list of reimbursable
products under a discrete category (NHS Drug Tariff Part IX) effective
October 01, 2016. The NHS provides to each resident of the UK medical care
in the primary (general practitioner GP) and secondary level (hospitals)
free of charge. Furthermore, in a declaration recently published the
Scottish Health Technologies Group (SHTG - a division of NHSScottland) has
clearly recommended the application of Granulox to all doctors working for
NHSScottland because of Granulox' efficacy and marked cost savings of
several thousand British pounds proved by several studies.

Michael Sander, Managing Director of SastoMed GmbH commented: "InFirst
Healthcare as our partner in the UK, has done an excellent job. Because of
the convincing data submitted a worldwide respected and efficient health
care system such as the NHS has not only appreciated the significant
improvement in the quality of life for millions of patients suffering from
chronic wounds, but also confirmed the significant cost reduction potential
by using Granulox. We see this as a breakthrough success, which will
integrated Granulox in modern wound treatment system not only in Great
Britain. In parallel InFirst is working hard on the approval for the US
market - even for that the extensive data from England constitute an
important basis ".

Sangui BioTech International, Inc. ("SGBI") is a holding company the
shares of which are being traded on the OTCQB venture stage marketplace for
early stage and developing U.S. and international companies (OTCQB: SGBI).
Companies are current in their reporting and undergo an annual verification
and management certification process. Sangui shares also trade on the OTC
markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its
purpose is to provide financing and access to the capital markets for the
enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.

For more information please contact:

Sangui Biotech International, Inc.

Thomas Striepe

Fax: [phone]

e-mail: [e-mail]

Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other "forward-looking" information. These statements
are subject to known and unknown risks, uncertainties, and other factors
that could cause the actual results to differ materially from those
contemplated by the statements. The forward-looking information is based on
various factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections include,
among many others, the ability of the Company to raise sufficient capital
to meet operating requirements. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," and variations of
such words and similar expressions are intended to identify such forward-
looking statements. Unless required by law, the Company undertakes no
obligation to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.


---------------------------------------------------------------------------

04.10.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

508425 04.10.2016